BEIKE BIOTECHNOLOGY

A Descriptive Statistical Report on 48 ONH and SOD Patients with Cell Therapy From 2007, 2008, and 2009

Background

This descriptive report covers subjective information collected by questionnaires from our overseas ONH and SOD patients confirmed before the hospital-admission. Participating patients were treated in 2007, 2008, and 2009. This information mainly includes the efficacy assessment of the cell therapy on five time points: immediately after the treatment, one month, three months, six months, and twelve months after the treatment. The data for this analysis is based solely on patients from 2007-2009 who submitted the questionnaire to our followup department.

Results

Age Structure: The mean age of the participating patients is 7.2 years (SD=7.2). All were diagnosed with ONH and/or SOD before coming to China. The age structure is shown in Chart 1 on page two. A majority of patients (82.3%) are under 10 years old.

General Effectiveness: General effectiveness was measured by a Yes/No question asked to the patient and/or the patient's caregiver. The question asked if the patient had any improvement at any time after the treatment. The general effectiveness percentage is 77%. The analysis results by age show that the effectiveness percentage of the under-10 year-old patients (34/40, 85%) is significantly higher than that of above-10 year-old patients (4/8, 50%) (X^2=4.7, P<0.05). This might imply that the chance of getting benefits from the cell therapy for elder patients is less than that for younger patients.

Improvement Immediately After the Treatment: The effectiveness rate at the time point immediately after the treatment is 29 out the 48 patients (60%).

Improvement at 1 Month, 3 Months, 6 Months, and 12 months: There were three patients at one month, three patients at three months, one patient at six months, and one patient at one year after the treatment that received their first improvements at these time points. A representation of these numbers can be seen on page two in Chart 2.

Conclusions

For the 48 patients, the general effectiveness percentage is 77% (percent of total patients that received improvement). 29 out of 48 patients received improvements immediately after treatment, while eight of the 48 patients received their first improvements at least one month after the treatment. 11 out of the 48 patients (23.4%) did not receive any improvements within a year after the treatment.

Chart 1: Ages of Patients





Chart 1: When Patients First Noticed Improvement (After Treatment)



Disclaimer: The information contained in this document is to be used solely as a reference for observing patients' subjective opinions and observations about treatment efficacy.

BEIKE BIOTECHNOLOGY CO., LTD.

9th Floor, Zhongke Building, 1 South Street South Area, Shenzhen Hi-Tech Industrial Park Shenzhen, China 518057

Tel: +86-755-8630-9277 Email: info@beikebiotech.com Fax: +86-755-8630-9309 Web: www.beikebiotech.com